Serum Omentin-1 Levels Research Articles

Evaluation of Visceral Adipokines: Omentin, Vaspin, and Visfatin in Patients with Gestational Diabetes Mellitus

Background: Gestational diabetes mellitus (GDM) is a common metabolic disorder characterized by glucose intolerance that develops during pregnancy. The underlying pathophysiological mechanisms of GDM involve complex interactions between genetic, environmental, and hormonal factors, including adipokines secreted by visceral adipose tissue. Omentin, vaspin, and visfatin are adipokines believed to influence insulin sensitivity and inflammation, though their precise relationship with GDM remains unclear. This study aimed to examine the association between these adipokines and GDM. Methods: This single-center, prospective controlled cohort study included 87 pregnant patients diagnosed with GDM via an oral glucose tolerance test (OGTT) between the 24th and 28th weeks of gestation, along with 87 control subjects without GDM. Serum levels of omentin, vaspin, and visfatin were measured using enzyme-linked immunosorbent assay (ELISA), and their association with GDM was analyzed. Results: Our results demonstrated that omentin levels were significantly higher in the GDM group compared to the control group (p = 0.012), while no significant differences were observed in vaspin and visfatin levels (p > 0.05). An omentin cut-off value of 29.0 ng/mL predicted GDM with 59.1% sensitivity and 59.1% specificity, suggesting its potential as a biomarker for GDM. Conclusions: This study underscores the unique role of omentin in GDM, in contrast to the non-significant changes observed in vaspin and visfatin levels. The elevated omentin levels in GDM patients suggest its potential as a biomarker for diagnosing and managing GDM. Further research is needed to elucidate the mechanisms through which omentin contributes to the pathophysiology of GDM. Clinical Trial Registration: NCT05463237, https://clinicaltrials.gov/study/NCT05463237.

Evaluation of Serum Adipokine Levels in Girls With Central Precocious Puberty.

Adipose tissue has an important endocrine function by secreting a variety of hormones known as adipokines, such as Visfatin, Omentin-1 and Chemerin. On the other hand, these hormones are also secreted from places other than fatty tissues in the girl's genital system. The goal of this study was to demonstrate the secretory status of adipokines in patients with central precocious puberty (CPP) and their utility in the diagnosis of precocious puberty. A total of 105 patients were included in the study (53 in the CPP group and 52 in the control group). The following were used as the CPP diagnostic criteria; breast development, basal LH measurement higher than 0.3 IU/L, peak LH level ≥ 5 IU/L, peak LH/FSH ratio ≥ 0.66 (after 0.1 mg GnRH stimulation test) and a difference of at least 1 year between bone and chronological age. A statistically significant difference was detected between the groups in serum Omentin-1 and Chemerin levels, and no significant differences were detected between the groups in Visfatin values. The cut-off values for the diagnosis of CPP were calculated as ≤ 48.9 with 81% sensitivity and 54% specificity for Omentin-1, and as ≥ 417 with 85% sensitivity and 60% specificity for Chemerin. In our study, we found that Omentin-1 level decreased and Chemerin level increased in lean girls with CPP. More studies are needed to elucidate how adipokines play roles in explaining the onset of CPP, and whether they may be used as a reliable marker for the diagnosis of CPP.

Efficacy of tibial cortex transverse transport in treating diabetic foot ulcer and its effect on serum omentin-1 and irisin levels

ObjectiveDiabetic foot ulcer (DFU) is a common and debilitating complication of diabetes that is associated with an increased risk of lower-limb amputation and a reduced life expectancy. Tibial cortex transverse transport (TTT) has become a newly alternative surgical method to facilitate ulcer healing and prevent lower limb amputation. Herein, we investigated the efficacy of TTT in treating DFU and changes of serum omentin-1 and irisin levels.MethodsThis study prospectively recruited 52 consecutive patients with DFU who were treated with TTT. The follow-up was performed weekly during the first 12 weeks postoperatively and every 3 months until 1 year after TTT. The serum levels of vascular endothelial growth factor (VEGF), omentin-1, and irisin in DFU patients undergoing TTT were determined by ELISA methods on the preoperative 1st day, postoperative 2nd week and 4th week.ResultsThe wound healing rate was 92.3% (48/52) at the 1-year follow-up. The visual analog scale (VAS) pain scores of patients showed a significant reduction at the 4th week after TTT (p < 0.001). The dorsal foot skin temperature, ankle brachial index, and dorsal foot blood flow of patients were significantly increased at the 4th week after TTT (p < 0.001). Results of ELISA methods showed the serum levels of VEGF, omentin-1, and irisin on the 2nd week and 4th week after TTT were notably elevated compared to the levels determined on the preoperative 1st day (p < 0.001). The serum levels of VEGF, omentin-1, and irisin on the 4th week after TTT were also significantly higher than the levels determined on the 2nd week after TTT (p < 0.001).ConclusionTTT could promote the wound healing and reduce the risk of lower limb amputation, demonstrating promising clinical benefits in the treatment of DFU. Increased expressions of serum proangiogenic factors including VEGF, omentin-1, and irisin were noted in the early stage after TTT, which may provide a new mechanism of TTT promoting wound heal.

Omentin-1 May Be One Treatment Factor for Intravenous Thrombolysis of Acute Cerebral Infarction Through the Inhibition of NLRP3 Ubiquitination by AMPK Function: Preliminary Findings.

Acute cerebral infarction (ACI) is a common neurological disease that is associated with high morbidity, disability and mortality rates. At present, antiplatelet therapy is a necessary treatment for ACI. The present study aimed to investigate the effects of omentin-1 on the intravenous thrombolysis of ACI. The present study aimed to investigate the effects of omentin-1 on the intravenous thrombolysis of ACI. The mouse model of ACI was induced using male C57BL/6 mice through middle cerebral artery occlusion (MCAO). Meanwhile, the murine BV2 microglial cells were pretreated with 0.1 mg/ml of lipopolysaccharide (LPS), and then induced with 2 mM of adenosine triphosphate (ATP). The omentin-1 mRNA expression in patients receiving intravenous thrombolysis for ACI was down-regulated compared with the normal group. Additionally, the serum level of omentin-1 was negatively correlated with National Institute of Health Stroke Scale (NIHSS) score or serum level of IL-1β or MMP-2 in patients receiving intravenous thrombolysis for ACI. Meanwhile, the serum mRNA expression of omentin-1 was positively correlated with Barthel index or high-sensitivity C-reactive protein (hs-CRP) in patients undergoing intravenous thrombolysis for ACI. As observed from the in vitro model, Omentin-1 reduced inflammation, promoted cell growth, alleviated ROS-induced oxidative stress, and enhanced AMPK activity through activating NLRP3 ubiquitination. Omentin-1 presented ACI in the mouse model of ACI. Regulating AMPK activity contributed to controlling the effects of Omentin-1 on the in vitro model. Omentin-1 reduced neuroinflammation and ROS-induced oxidative stress in the mouse model of ACI, which was achieved by inhibiting NLRP3 ubiquitination through regulating AMPK activity. Therefore, omentin-1 may serve as a treatment factor for the intravenous thrombolysis of ACI in further clinical application.

Omentin associates with serum metabolite profiles indicating lower diabetes risk: KORA F4 Study

IntroductionCirculating omentin levels have been positively associated with insulin sensitivity. Although a role for adiponectin in this relationship has been suggested, underlying mechanisms remain elusive. In order to reveal the...

The Relationship between Omentin Gene (ITLN1) Variant rs190234680 and Serum Omentin levels in patients with Diabetic Foot

Diabetic foot is a common and serious complication of diabetes, characterized by neuropathy, ischemia, and infections which can lead to amputation of the affected limb. Omentin is a protein that is predominantly expressed in adipose tissue and has been implicated in insulin sensitivity and glucose metabolism. Low plasma omentin levels have been associated with several metabolic disorders, including T2DM. Objectives: Study objective were to assess the pattern of omentin-1 [ITLN1] single nucleotide gene polymorphism in diabetic foot patients compared to uncomplicated T2DM. It also sought to compare the serum omentin-1 levels between diabetic foot patients and those with uncomplicated Type 2 diabetes mellitus and determine the association between omentin levels and the clinical staging of diabetic foot patients. Methodology: In this cross-sectional analytical study, 130 participants of DF and T2DM were enrolled. Omentin (ITLN1) gene polymorphism(rs190234680) was determined by sequencing and serum omentin levels were estimated by ELISA. Result: A significant association was observed between the GG genotype (wild type) of the omentin (ITLN1) gene and diabetic foot, while no significant difference was found in serum omentin levels between cases and controls. The analysis did not provide clear evidence of a significant relationship between omentin levels in different grades of diabetic foot Conclusion:The study suggested that the GG genotype of omentin 1 gene may be an important risk factor in development of diabetic foot in patients with type 2 diabetes. However, there was no significant difference in serum omentin levels between different stages of diabetic foot.

Association between serum omentin-1 and mucosal disease activity in patients with ulcerative colitis.

Mucosal inflammation is a key feature of ulcerative colitis (UC), a chronic relapsing and remitting form of inflammatory bowel disease. Omentin-1, a newly discovered adipokine, is reported to have anti-inflammatory effects and has been found to be decreased in patients with inflammatory bowel disease. The aim of our study was to investigate the association between serum omentin-1 levels and mucosal disease activity in patients with UC. A total of 126 patients with UC and 77 healthy volunteers were enrolled in the study. Serum omentin-1 expression levels were measured using enzyme-linked immunosorbent assay to evaluate its potential for monitoring disease activity, including clinical and endoscopic activity. Serum omentin-1 levels were significantly lower in patients with UC compared to healthy controls (HC) (UC, 61.7 interquartile range: 51.5-72.6 versus healthy controls, 103.5 interquartile range: 48.3-156.2ng/ml; P < .001). Furthermore, serum omentin-1 levels were associated with both clinical and endoscopic activity in patients with UC. Notably, omentin-1 levels were significantly lower in patients who achieved mucosal healing. Receiver operating characteristic curves indicated that serum omentin-1 levels could potentially serve as an activity index for evaluating UC. These findings provide further insight into the association between omentin-1 and UC, suggesting that omentin-1 may be a useful biomarker for monitoring mucosal disease activity in patients with UC.

Оментин-1 и ишемическая болезнь сердца

Aim. The purpose of the review is to summarize the results of studies on the relationship between the level of omentin-1 and coronary artery disease (CAD). Key points. Adipose tissue is currently considered as an endocrine organ synthesizing biologically active factors known as adipocytokines, which may be involved in the pathogenesis of obesity-related metabolic and cardiovascular diseases, in particular, CAD. Omentin-1 is an adipocytokine that is predominantly secreted by visceral adipose tissue and plays an important role in the development of chronic inflammatory diseases, including CAD. Two isoforms of omentin are known: omentin-1 and omentin-2. Omentin-1 is the main circulating form of omentin. Its blood level in healthy people, according to different authors, varies from 1.61 to 815.3 ng/ml. A number of studies have found that the concentration of omentin-1 in the blood of women is higher than that of men, which may be due to sexual dimorphism of adipose tissue. The results of the studies indicate that the levels of omentin-1 circulating in the blood are associated with various metabolic risk factors. The review describes the main molecular mechanisms that determine these effects of omentin-1. A decrease in serum omentin-1 levels can be considered as an independent predictor of CAD and correlates with the severity and prognosis of this disease. A number of studies have established an association between the carriage of various variants of the omentin-1 (ITLN1) gene, CAD and obesity. The article analyzes the available data on the role of the level of omentin-1 in CAD, determined not only in the blood, but also in subcutaneous and visceral adipose tissue. The possible prospects for the use of various molecules capable of increasing the level of omentin-1 in the blood are analyzed. Conclusion. A decrease in the level of omentin-1 may be an independent predictor of CAD and is associated with the severity and progression of the disease. It is likely that omentin-1 can act as an alternative diagnostic tool to ensure optimal management of patients with CAD. Studies of the effect of omentin-1 on the prognosis in patients with various forms of CAD are largely ambiguous and therefore further, more comprehensive studies are needed. Keywords: coronary artery disease, acute coronary syndrome, omentin-1, adipokines, subcutaneous and visceral adipose tissue, omentin-1 gene (ITLN1).

Relationship between serum omentin-1 levels and nascent metabolic syndrome in Caucasian patients with obesity.

omentin-1 might present a potential role in metabolic syndrome (MS). The aim of our investigation was to evaluate the relationship between omentin-1 and nascent MS. we carried out a cross-sectional study in 606 obese subjects. Adiposity parameters, blood pressure, fasting blood glucose, insulin levels, insulin resistance (HOMA-IR), triglyceride and glucose index (TyG), lipid profile, C-reactive protein, omentin-1, and prevalence of nascent MS were determined. 307 subjects had MS (49.2 %) and 299 did not show MS (50.8 %). Subjects without MS have higher omentin-1 levels (delta: 78.0 ± 13.8 ng/ml; p = 0.01). A negative correlation was observed between omentin-1 and adiposity parameters, glucose, insulin, HOMA-IR, TyG index and triglycerides in both groups. And a positive correlation was observed with HDL-cholesterol. BMI (OR = 1.17, 95 % CI = 1.09-1.31; p = 0.02), HOMA-IR (OR = 5.21, 95 % CI = 1.69-21.11; p = 0.01) and omentin-1 (OR = 0.95, 95 % CI = 0.94-0.97; p = 0.02) remained in the final model as predictors of MS. The cut-off point according to the Youden index was 372.45 ng/ml of omentin-1, to predict MS. Caucasian patients with obesity had clearly lower serum omentin-1 levels in the presence of nascent MS. An inverse correlation was demonstrated with adiposity parameters, insulin resistance and triglycerides. And a direct correlation with HDL-cholesterol was reported.

Serum omentin-1 is correlated with the severity of liver disease in patients with chronic hepatitis C.

Patients with chronic hepatitis C virus (HCV) infection have increased serum omentin-1. Omentin-1 is an anti-inflammatory adipokine, and higher levels may be a direct effect of HCV infection. Successful elimination of HCV by direct acting antivirals almost normalized circulating levels of various molecules with a role in inflammation. To evaluate the effect of HCV infection on serum omentin-1, serum omentin-1 levels of HCV patients were measured before therapy and at 12 wk after therapy end. Associations of serum omentin-1 with parameters of inflammation and liver function were explored at both time points. Serum omentin-1 levels of patients with and without liver cirrhosis, which was defined by ultrasound or the fibrosis-4 (FIB-4) score, were compared. Serum omentin-1 levels were measured by enzyme-linked immunosorbent assay in 84 chronic HCV patients before therapy and at 12 wk after therapy end where sustained virological response 12 (SVR12) was achieved in all patients. Serum omentin-1 of 14 non-infected controls was measured in parallel. In patients with chronic HCV, serum omentin-1 levels were not related to viral load or viral genotype. HCV patients with liver steatosis and HCV patients with diabetes had serum omentin-1 levels comparable to patients not suffering from these conditions. Serum omentin-1 levels at SVR12 were similar in comparison to pretreatment levels. In addition, serum levels did not differ between HCV-infected patients and non-infected controls. Serum omentin-1 levels did not correlate with leukocyte count or C-reactive protein. Positive correlations of serum omentin-1 with bilirubin and the model for end-stage liver disease score (MELD) were detected before therapy and at SVR12 in the whole cohort. Bilirubin and the MELD score also positively correlated with serum omentin-1 levels in the subgroup of patients with ultrasound diagnosed liver cirrhosis before therapy. At SVR12, serum omentin-1 levels of patients with liver cirrhosis negatively correlated with albumin. Before therapy start, patients with high FIB-4 scores had increased serum omentin-1 in comparison to patients with a low score. Serum omentin-1 levels of patients with liver cirrhosis defined by ultrasound were increased at baseline and at SVR12. Present study showed that liver cirrhosis, but not HCV infection per se, is related to elevated serum omentin-1 levels.

Association of serum omentin levels with microvascular complications of type 2 diabetes mellitus: a systematic review and meta-analysis.

Type 2 diabetes mellitus (T2DM) is a chronic condition associated with various microvascular complications, including neuropathy, retinopathy, and nephropathy. Recent studies have suggested a potential association between serum omentin levels and the risk of developing microvascular complications in patients with T2DM. However, the existing evidence remains inconclusive. Therefore, we conducted a systematic review and meta-analysis to examine the association between serum omentin levels and microvascular complications in T2DM patients. A comprehensive search was conducted in PubMed, Scopus, and Google Scholar databases to retrieve relevant articles published up to May 2023. Observational studies investigating omentin levels association with microvascular complications in T2DM patients were included. Data was extracted and hence analyzed. A total of seven cross-sectional articles met the inclusion criteria, with a total population of 1587 participants. The meta-analysis revealed a significant association between serum omentin levels and microvascular complications in patients with T2DM. Serum omentin levels were lower in patients with microvascular complications than in those without complications (Mean difference, 95% confidence interval: -1.31 [-2.50, -0.13], I2 = 99.62%). This systematic review and meta-analysis provides evidence supporting an association between serum omentin levels and microvascular complications in patients with T2DM. The findings suggest that Omentin may be lower in T2DM patients with microvascular complications. Further research is warranted to elucidate the underlying mechanisms and explore the clinical implications of these findings. The online version contains supplementary material available at 10.1007/s40200-023-01359-2.

Assessing evening primrose oil effects on the serum levels of omentin-1 and biochemical parameters in the diabetic rat model

Assessing evening primrose oil effects on the serum levels of omentin-1 and biochemical parameters in the diabetic rat model

Adipokines and Their Role in Heart Failure: A Literature Review.

Obesity is a major risk factor for heart failure (HF). The relationship between adipokines and HF has been implicated in many previous studies and reviews. However, this review article summarizes the basic role of major adipokines, such as apelin, adiponectin, chemerin, resistin, retinol-binding protein 4 (RBP4), vaspin, visfatin, plasminogen activator inhibitor-1, monocyte chemotactic protein-1, nesfatin-1, progranulin, leptin, omentin-1, lipocalin-2, and follistatin-like 1 (FSTL1), in the pathogenesis of HF. Apelin is reduced in patients with HF and upregulated following favorable left ventricular (LV) remodeling. Higher levels of adiponectin have been found in patients with HF compared to in control patients. Also, high plasma chemerin levels are linked to a higher risk of HF. Serum resistin is related to the severity of HF and associated with a high risk for adverse cardiac events. Evidence indicates that RBP4 can contribute to inflammation and damage heart muscle cells, potentially leading to HF. Vaspin might stop the progression of cardiac degeneration, fibrosis, and HF according to experiments on rats with experimental isoproterenol-induced chronic HF. The serum concentrations of visfatin are significantly lower in patients with systolic HF. Leptin levels were found to be correlated with low LV mass and myocardial stiffness, both of which are significant risk factors for the development of HF with preserved ejection fraction (HFpEF). Measuring serum omentin-1 levels appears to be a novel prognostic indicator for risk stratification in HF patients. Increased expression of neutrophil gelatinase-associated lipocalin in both systemic circulation and myocardium in clinical and experimental HF suggests that innate immune responses may contribute to the development of HF. FSTL1 was elevated in patients with HF with reduced ejection fraction and associated with an increase in the size of the left ventricle of the heart. However, other adipokines, such as plasminogen activator inhibitor-1, monocyte chemotactic protein-1, nesfatin-1, and progranulin, have not yet been studied for HF.

Serum Omentin-1 Levels in Obese Adolescents with Vitamin D Deficiency: A Prospective Cross-sectional Study

Background: Vitamin D deficiency is common in obese adolescents. It modulates the release of omentin 1 from adipose tissue. We believe that both vitamin D and omentin 1 affect each other in adipose tissue via inflammation. Objectives: This study aimed to examine serum omentin-1 levels in obese adolescents with vitamin D (Vit D) deficiency. Methods: In this cross-sectional prospective study, 83 obese adolescents were included. Serum 25-hydroxy vitamin D (25(OH)D) concentrations, fasting glucose, and lipid profiles of obese adolescents were studied. At the same time, blood was drawn into a separate tube to study the omentin 1 level. Of the 83 obese cases, 45 with 25(OH)D concentrations below 20 ng/mL were considered as the study group, and 38 with 25(OH)D concentrations ≥ 20 ng/mL as the control group. Serum omentin-1 levels were evaluated and compared. Results: The average 25(OH)D value in the study and control groups was 17.14 ± 2.22 ng/mL and 45.29 ± 24.98 ng/mL, respectively. The average omentin-1 concentration of the control group was 262.5 ± 136.31 ng/mL, and the mean omentin-1 level of the study group was 113.23 ± 15.98 ng/mL. The mean omentin-1 concentrations of the study group were significantly lower compared to the control group (P = 0.0001). There was a significant and positive correlation between omentin-1 and 25(OH)D (r = 0.988, P = 0.0001). In univariate tests, linear regression analysis was carried out with 25(OH)D and omentin-1, and 25(OH)D displayed a significant positive correlation (P = 0.0001). The optimal cut-off point for the serum omentin-1 concentration was 135.01 ng/mL. No significant correlation was determined between omentin-1 and body mass index, lipid profile, glucose, and insulin variables (P &gt; 0.05). Conclusions: We showed significantly low concentrations of serum omentin-1 in obese adolescents with vitamin D deficiency. Serum omentin-1 can be employed as a biomarker in obese adolescents with vitamin D deficiency.

Effect of high-intensity interval training on omentin-1 serum levels, gene expression, and insulin resistance in type 2 diabetic rats

Effect of high-intensity interval training on omentin-1 serum levels, gene expression, and insulin resistance in type 2 diabetic rats

The effect of exercise training on serum Omentin-1 levels, glycemic control and body composition in adults population: a systematic review and meta-analysis of randomized controlled trials

The effect of exercise training on serum Omentin-1 levels, glycemic control and body composition in adults population: a systematic review and meta-analysis of randomized controlled trials

Correlation of serum omentin-1 level with clinical features and major adverse cardiac and cerebral events in patients undergoing continuous ambulatory peritoneal dialysis

Omentin-1 shows a critical protective role of cardiovascular events in chronic kidney disease. This study aimed to further assess serum omentin-1 level and its relationship with clinical features and accumulating major adverse cardiac/cerebral events (MACCE) risk in end-stage renal disease patients undergoing continuous ambulatory peritoneal dialysis (CAPD-ESRD). Totally, 290 CAPD-ESRD patients and 50 healthy controls (HCs) were recruited, and their serum omentin-1 levels were measured by enzyme-linked immunosorbent assay. All CAPD-ESRD patients were followed up for 36 months to assess accumulating MACCE rate. Omentin-1 level in CAPD-ESRD patients was lower than that in HCs [median (interquartile range): 229.350 (153.575–355.550) vs. 449.800 (354.125–527.450) pg/mL] (p < 0.001). Moreover, omentin-1 level was inversely related to C-reactive protein (CRP) (p = 0.028), total cholesterol (p = 0.023), and low-density lipoprotein cholesterol (p = 0.005), while there was no correlation in omentin-1 level with other clinical features in CAPD-ESRD patients. The accumulating MACCE rate was 4.5%, 13.1%, and 15.5% in the first, second, and third years respectively, and it was lower in CAPD-ESRD patients with high level of omentin-1 than those with low level of omentin-1 (p = 0.004). Furthermore, omentin-1 (hazard ratio (HR)=0.422, p = 0.013) and high-density lipoprotein cholesterol (HR = 0.396, p = 0.010) were independently associated with reduced accumulating MACCE rate; while age (HR = 3.034, p = 0.006), peritoneal dialysis duration (HR = 2.741, p = 0.006), CRP (HR = 2.289, p = 0.026), serum uric acid (HR = 2.538, p = 0.008) were independently related to higher accumulating MACCE rate in CAPD-ESRD patients. In conclusion, serum high omentin-1 level is associated with decreased inflammation, lipid levels, and accumulating MACCE risk in CAPD-ESRD patients.

Human Omentin-1 Administration Ameliorates Hypertensive Complications without Affecting Hypertension in Spontaneously Hypertensive Rats.

Hypertension is one of the major risk factors for cardiovascular diseases and is caused by various abnormalities including the contractility of blood vessels. Spontaneously hypertensive rats (SHR), whose systemic blood pressure increases with aging, are a frequently used animal model for investigating essential hypertension and related complications in humans due to the damage of several organs. Human omentin-1 is an adipocytokine consisting of 313 amino acids. Serum omentin-1 levels decreased in hypertensive patients compared with normotensive controls. Furthermore, omentin-1 knockout mice showed elevated blood pressure and impaired endothelial vasodilation. Taken together, we hypothesized that adipocytokine, human omentin-1 may improve the hypertension and its complications including heart and renal failure in the aged SHR (65-68-weeks-old). SHR were subcutaneously administered with human omentin-1 (18 μg/kg/day, 2 weeks). Human omentin-1 had no effect on body weight, heart rate, and systolic blood pressure in SHR. The measurement of isometric contraction revealed that human omentin-1 had no influence on the enhanced vasocontractile or impaired vasodilator responses in the isolated thoracic aorta from SHR. On the other hand, human omentin-1 tended to improve left ventricular diastolic failure and renal failure in SHR. In summary, human omentin-1 tended to improve hypertensive complications (heart and renal failure), while it had no influence on the severe hypertension in the aged SHR. The further study of human omentin-1 may lead to the development of therapeutic agents for hypertensive complications.

The impact of high intensity interval training on serum omentin-1 levels, lipid profile, and insulin resistance in obese men with type 2 diabetes mellitus

BACKGROUND: High-intensity interval training (HIIT) is an effective exercise method that could lead to favorable changes in obese and diabetic subjects. OBJECTIVE: To investigate the effects of HIIT on serum omentin-1 levels, lipid profile, and insulin resistance in diabetic obese men. METHODS: Fifty obese men suffering from T2DM with ages between 40 and 60 years were enrolled. Subjects were divided into two groups: the HIIT (n= 26) and control group (n= 24). The HIIT group subjects underwent 12 weeks (3 sessions per week) of HIIT program, while the control group subjects kept to their normal daily activities. Fasting blood glucose levels, serum omentin-1 levels, lipid profile, and insulin resistance were evaluated at baseline and after the experiment. RESULTS: HIIT resulted in significant improvements in the subjects’ body composition, serum omentin-1 levels, lipid profiles, fasting insulin, HOMA-IR (p&lt; 0.05). Further, highly significant negative correlations were observed between serum omentin levels, on the one hand, and body mass index, body weight, and waist circumference, on the other. CONCLUSIONS: Twelve weeks of HIIT may be an effective training strategy to improve serum omentin-1 levels, body composition, lipid profile, and insulin sensitivity in diabetic obese men.

Association of Serum Omentin-1 Concentration with the Content of Adipose Tissue and Glucose Tolerance in Subjects with Central Obesity

Omentin is one of the few adipokines with potentially beneficial metabolic effects. The main aim of this study was to determine the association between serum omentin-1 levels and the occurrence of central obesity and abnormal glucose tolerance, taking into account gender. The study involved 88 participants aged 30-60, including 47 women and 41 men. Two subgroups among the obese subjects were distinguished-those with normal and abnormal glucose tolerance. Anthropometric and biochemical examinations and blood pressure measurements were performed. Omentin-1 concentrations were significantly lower among patients with obesity compared to those without obesity (p = 0.027) and, similarly, comparing men with abnormal glucose tolerance with men with normal glucose tolerance (p = 0.035). In contrast, no such pattern was observed in women. The multivariable regression model showed a significant effect of gender status and important factors of tissue insulin sensitivity, such as OGGT results, WHR and amount of body fat, on the variability of serum omentin-1 concentration in the entire study population (R2adj. = 13.7%; p = 0.003). High omentin-1 levels found in men with obesity and normal glucose tolerance suggest that omentin-1 protects against metabolic disorders associated with obesity in the male population.